Abstract
Background Many diseases are associated with chronic inflammation, resulting in widening indications for anti-inflammatory therapies. Whilst effective as disease modifying agents, these increase the risk of serious infection.
Objective To determine if low-grade inflammation is associated with fatal infection, irrespective of associated comorbidity or anti-inflammatory therapy.
Design Observational cohort study
Setting UK Biobank study
Participants 461,052 people
Interventions None
Measurements Incidence rate ratio (IRR) of death from infection, cardiovascular disease, or other causes, adjusted for comorbidities and use of anti-inflammatory therapies, for serum C-reactive protein (CRP) at recruitment.
Results Low grade inflammation was common in all morbidities considered and was more prevalent as multimorbidity accrued (CRP ≥2mg/L in 23.3% of people without disease and 58.7% with 3+ comorbidities; p<0.001). After adjusting for confounding factors, CRP ≥2mg/L was associated with a higher IRR of infection death (IRR 1.70; 95% confidence interval 1.51-1.92) than cardiovascular death (IRR 1.48; 1.40-1.57) or other causes of death (IRR 1.41; 1.37-1.45); CRP thresholds of ≥5 and ≥10 mg/L yielded similar findings. Absolute rates of infection, cardiovascular and other death were 0.43, 1.59 and 5.39 per 1000 participant-years, respectively, in people with CRP ≥2mg/L. Analyses stratified by disease type, or number of comorbidities, showed consistent associations between elevated CRP and infection death.
Limitations Our observational study design precludes assessment of causality. We lacked data on the use of anti-inflammatory therapies after study recruitment.
Conclusion Low grade inflammation, irrespective of associated comorbidity, identifies people at particularly increased risk of infection death. Decisions to use anti-inflammatory therapies guided by low grade inflammation require careful consideration of the associated risks and benefits.
Competing Interest Statement
AWM has undertaken consultancy work on behalf of the University of Leeds in relation to giant cell arteritis for Roche, Chugai, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Astra Zeneca and Vifor and has received research funding from Roche. MTK has received speaker fees from Merck, Novo Nordisk and unrestricted research awards from Medtronic. KKW has undertaken consultancy work for Medtronic and Cardiac Dimensions; acted as an investigator and steering committee member for studies coordinated by Novartis, Medtronic; and has received speaker fees from Cardiac Dimensions, Medtronic, Microport, Abbott, Pfizer, Bayer and BMS. MPR is currently employed by Union Chimique Belge (UCB) Biopharma. All other authors have no disclosures.
Funding Statement
This work was supported by the British Heart Foundation (FS/18/44/33792 and FS/12/80/29821). AWM was additionally supported by the NIHR Leeds Biomedical Research Centre and Diagnostic Evaluation Co-operative and a NIHR Senior Investigator award; the views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from UK Biobank (https://www.ukbiobank.ac.uk)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: British Heart Foundation FS/18/44/33792 and FS/12/80/29821
Data Availability
All data produced in the present study are available upon application to UK Biobank (https://www.ukbiobank.ac.uk)
